1. Home
  2. BTCT vs IMRN Comparison

BTCT vs IMRN Comparison

Compare BTCT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

HOLD

Current Price

$0.52

Market Cap

11.4M

Sector

Real Estate

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.06

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTCT
IMRN
Founded
2006
1994
Country
Singapore
Australia
Employees
26
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4M
9.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BTCT
IMRN
Price
$0.52
$1.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
319.0K
40.5K
Earning Date
05-29-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$283.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.68
52 Week High
$3.12
$2.38

Technical Indicators

Market Signals
Indicator
BTCT
IMRN
Relative Strength Index (RSI) 25.18 42.55
Support Level N/A $0.96
Resistance Level $1.21 $1.24
Average True Range (ATR) 0.06 0.09
MACD -0.02 -0.01
Stochastic Oscillator 1.12 7.48

Price Performance

Historical Comparison
BTCT
IMRN

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: